Modulation of HERG potassium channel function by drug action

Annals of Medicine

Volumn 36, Issue SUPPL. 1, 2004, Pages 41-46

  Thomas, Dierk ^a   Karle, Christoph A ^a   Kiehn, Johann ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Action potentials; Antiarrhythmic drugs; Arrhythmia; Binding sites; Delayed rectifier potassium channel; HERG protein; Long QT syndrome; Torsade de pointes

Indexed keywords

1' (6 CYANO 1,2,3,4 TETRAHYDRO 2 NAPHTHYL) 3,4 DIHYDRO 6 METHANESULFONAMIDOSPIRO[2H 1 BENZOPYRAN 2,4' PIPERIDIN] 4 OL; AMIODARONE; AMITRIPTYLINE; ASTEMIZOLE; AZIMILIDE; BERTOSAMIL; CHLORPROMAZINE; CISAPRIDE; DOFETILIDE; FLUOXETINE; HALOPERIDOL; IMIPRAMINE; KETOCONAZOLE; POTASSIUM CHANNEL HERG; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SOTALOL; TAMOXIFEN; TERFENADINE;

ACTION POTENTIAL; CONFERENCE PAPER; DISEASE ASSOCIATION; DRUG EFFECT; GENETIC CODE; GENETIC IDENTIFICATION; HEART ARRHYTHMIA; HEART MUSCLE CELL; HEART REPOLARIZATION; HUMAN; POTASSIUM CURRENT; PRIORITY JOURNAL; RISK FACTOR; SUDDEN DEATH; TORSADE DES POINTES;

EID: 2442638841     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.1080/17431380410032580     Document Type: Conference Paper

References (55)

1. + current. J Gen Physiol 1990;96:195-215.
2. Warmke JW, Ganetzky B. A family of potassium channel genes related to eag in Drosophila and mammals. Proc Natl Acad Sci USA 1994;91:3438-42.
3. Sanguinetti MC, Jiang C, Curran ME, Keating MT. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 1995;81:299-307.
4. Kiehn J, Lacerda AE, Wible BA, Brown AM. Molecular physiology and pharmacology of HERG. Single-channel currents and block by dofetilide. Circulation 1996;94:2572-9.
5. Abbott GW, Sesti F, Splawski I, Buck ME, Lehmann MH, Timothy KW, et al. MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell 1999;97:175-87.
6. Weerapura M, Nattel S, Chartier D, Caballero R, Hebert TE. A comparison of currents carried by HERG, with and without coexpression of MiRP1, and the native rapid delayed rectifier current. Is MiRP1 the missing link? J Physiol 2002;540:15-27.
7. Spector PS, Curran ME, Keating MT, Sanguinetti MC. Class III antiarrhythmic drugs block HERG, a human cardiac delayed rectifier K+ channel. Open-channel block by methanesulfonanilides. Circ Res 1996;78:499-503.
8. Hondeghem LM, Snyders DJ. Class III antiarrhythmic agents have a lot of potential but a long way to go-reduced effectiveness and dangers of reverse use-dependence. Circulation 1990;81:686-90.
9. Kiehn J, Thomas D, Karle CA, Schöls W, Kübler W. Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels. Naunyn-Schmiedebergs Arch Pharmacol 1999;359:212-19.
10. Busch AE, Eigenberger B, Jurkiewicz NK, Salata JJ, Pica A, Suessbrich H, et al. Blockade of HERG channels by the class III antiarrhythmic azimilide: mode of action. Br J Pharmacol 1998;123:23-30.
11. Numaguchi H, Mullins FM, Johnson JP, Jr, Johns DC, Po SS, Yang IC, et al. Probing the interaction between inactivation gating and D-sotalol block of HERG. Circ Res 2000;87:1012-8.
12. Thomas D, Wendt-Nordahl G, Röckl K, Ficker E, Brown AM, Kiehn J. High-affinity blockade of HERG human cardiac potassium channels by the novel antiarrhythmic drug BRL-32872. J Pharmacol Exp Ther 2001;297:753-61.
13. Zitron E, Karle CA, Wendt-Nordahl G, Kathofer S, Zhang W, Thomas D, et al. Bertosamil blocks HERG potassium channels in their open and inactivated states. Br J Pharmacol 2002;137:221-8.
14. Napolitano C, Priori S, Schwartz P. Torsade de pointes. Mechanisms and management. Drugs 1994;47:51-65.
15. Ficker E, Thomas D, Viswanathan PC, Dennis AT, Priori SG, Napolitano C, et al. Novel characteristics of a misprocessed mutant HERG channel linked to hereditary long QT syndrome. Am J Physiol 2000;279:H1748-56.
16. Sanguinetti MC, Curran ME, Spector PS, Keating MT. Spectrum of HERG K+-channel dysfunction in an inherited cardiac arrhythmia. Proc Natl Acad Sci USA 1996;93:2208-12.
17. Viskin S. Long QT syndromes and torsade de pointes. Lancet 1999;354:1625-33.
18. Teschemacher AG, Seward EP, Hancox JC, Witchel HJ. Inhibition of the current of heterologously expressed HERG potassium channels by imipramine and amitriptyline. Br J Pharmacol 1999;128:479-85.
19. Thomas D, Gut B, Wendt-Nordahl G, Kiehn J. The anti-depressant drug fluoxetine is an inhibitor of human ether-a-go-go-related gene (HERG) potassium channels. J Pharmacol Exp Ther 2002;300:543-8.
20. Suessbrich H, Waldegger S, Lang F, Busch AE. Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole. FEBS Lett 1996;385:77-80.
21. Thomas D, Gut B, Karsai S, Wimmer AB, Wu K, Wendt-Nordahl G, et al. Inhibition of cloned HERG potassium channels by the antiestrogen tamoxifen. Naunyn-Schmiedebergs Arch Pharmacol 2003:in press.
22. Kang J, Wang L, Chen XL, Triggle DJ, Rampe D. Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. Mol Pharmacol 2001;59:122-6.
23. Suessbrich H, Schonherr R, Heinemann SH, Attali B, Lang F, Busch AE. The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytes. Br J Pharmacol 1997;120:968-74.
24. Thomas D, Wu K, Kathöfer S, Katus HA, Schoels W, Kiehn J, et al. The antipsychotic drug chlorpromazine inhibits HERG potassium channels. Br J Pharmacol 2003;139:567-74.
25. Priori S, Napolitano C, Paganini V, Cantu F, Schwartz P. Molecular biology of the long QT syndrome: impact on management Pacing. Clin Electrophysiol 1997;20:2052-7.
26. Thomas D, Zhang W, Karle CA, Kathofer S, Schols W, Kiehn J. Deletion of protein kinase A phosphorylation sites in the HERG potassium channel inhibits activation shift by protein kinase A. J Biol Chem 1999;274:27457-62.
27. Cui J, Melman Y, Palma E, Fishman GI, McDonald TV. Cyclic AMP regulates the HERG K(+) channel by dual pathways. Curr Biol 2000;10:671-4.
28. Karle CA, Zitron E, Zhang W, Kathöfer S, Schoels W, Kiehn J. Rapid component I(Kr) of the guinea-pig cardiac delayed rectifier K(+) current is inhibited by beta(1)-adrenoreceptor activation, via cAMP/protein kinase A-dependent pathways. Cardiovasc Res 2002;53:355-62.
29. Thomas D, Zhang W, Wu K, Wimmer AB, Gut B, Wendt-Nordahl G, et al. Regulation of HERG potassium channel activation by protein kinase C independent of direct phosphorylation of the channel protein. Cardiovasc Res 2003;59:14-26.
30. Zhang Y, Wang H, Wang J, Han H, Nattel S, Wang Z. Normal function of HERG K(+) channels expressed in HEK 293 cells requires basal protein kinase B activity. FEBS Lett 2003;534:125-32.
31. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 2003;58:32-45.
32. Smith PL, Baukrowitz T, Yellen G. The inward rectification mechanism of the HERG cardiac potassium channel. Nature 1996;379:833-5.
33. Kiehn J, Lacerda AE, Brown AM. Pathways of HERG inactivation. Am J Physiol 1999;277:H199-210.
34. Snyders DJ, Chaudhary A. High affinity open channel block by dofetilide of HERg expressed in a human cell line. Mol Pharamacol 1996;49:949-55.
35. + channels. Circ Res 1998;82:386-95.
36. Lees-Miller JP, Duan Y, Teng GQ, Duff HJ. Molecular determinant of high-affinity dofetilide binding to HERG1 expressed in Xenopus oocytes: Involvement of S6 sites. Mol Pharmacol 2000;57:367-74.
37. Weerapura M, Hebert TE, Nattel S. Dofetilide block involves interactions with open and inactivated states of HERG channels. Pflügers Arch 2002;443:520-31.
38. Ulens C, Tytgat J. Redox state dependency of HERGS631C channel pharmacology: relation to C-type inactivation. FEBS Lett 2000;474:111-5.
39. Mitcheson JS, Chen J, Sanguinetti MC. Trapping of a methanesulfonanilide by closure of the HERG potassium channel activation gate. J Gen Physiol 2000;115:229-40.
40. Del Camino D, Holmgren M, Liu Y, Yellen G. Blocker protection in the pore of a voltage-gated K+ channel and its structural implications. Nature 2000;403:321-5.
41. Dumaine R, Roy ML, Brown AM. Blockade of HERG and Kv1.5 by ketoconazole. J Pharmacol Exp Ther 1998;286:727-35.
42. Mitcheson JS, Chen J, Lin M, Culberson C, Sanguinetti MC. A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci USA 2000;97:12329-33.
43. Doyle DA, Morais Cabrai J, Pfuetzner RA, Kuo A, Gulbis JM, Coher SL, et al. The structure of the potassium channel: molecular basis of K+ conduction and selectivity. Science 1998;280:69-77.
44. Keating MT, Sanguinetti MC. Molecular and cellular mechanisms of cardiac arrhythmias. Cell 2001;104:569-80.
45. Sanchez-Chapula JA, Navarro-Polanco RA, Culberson C, Chen J, Sanguinetti MC. Molecular determinants of voltage-dependent human ether-a-go-go-related gene (HERG) K+ channel block. J Biol Chem 2002;277:23587-95.
46. Sanchez-Chapula JA, Ferrer T, Navarro-Polanco RA, Sanguinetti MC. Voltage-dependent profile of human ether-a-go-go-related gene channel block is influenced by a single residue in the S6 transmembrane domain. Mol Pharmacol 2003;63:1051-8.
47. Picker E, Jarolimek W, Brown AM. Molecular determinants of inactivation and dofetilide block in ether-a-go-go (EAG) channels and EAG-related K(+) channels. Mol Pharmacol 2001;60:1343-8.
48. Chen J, Seebohm G, Sanguinetti MC. Position of aromatic residues in the S6 domain, not inactivation, dictates cisapride sensitivity of HERG and eag potassium channels. Proc Natl Acad Sci USA 2002;99:12461-6.
49. Starmer CF. Theoretical characterization of ion channel blockade. Competitive binding to periodically accessible receptors. Biophys J 1987;52:405-12.
50. Dorian P, Newman D. Rate dependence of the effect of antiarrhythmic drugs delaying cardiac repolarization: an overview. Europace 2000;2:277-85.
51. Bril A, Gout B, Bonhomme M, Landais L, Faivre JF, Linee P, et al. Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: experimental profile of BRL-32872. J Pharmacol Exp Ther 1996;276:637-46.
52. + channels involved in long QT syndromes, are targets for calcium channel blockers. Mol Pharmacol 1998;54:695-703.
53. Zhang S, Zhou Z, Gong Q, Makielski JC, January CT. Mechanism of block and identification of the verapamil binding domain to HERG potassium channels. Circ Res 1999;84:989-98.
54. Karle CA, Kreye VAW, Thomas D, Rockl K, Kathofer S, Zhang W, et al. Antiarrhythmic drug carvedilol inhibits HERG potassium channels. Cardiovasc Res 2001;49:361-70.
55. Sesti F, Abbott GW, Wei J, Murray KT, Saksena S, Schwartz PJ, et al. A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc Natl Acad Sci USA 2000;97:10613-8.